Beta-Blockers in Takotsubo Syndrome Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

Also called NCT06509074

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06509074
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06509074. Randomized; single masking; primary purpose treatment. Start 2024-08 (anticipated); primary completion 2025-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Beta-Blockers in Takotsubo Syndrome Study
Acronym
β-Tako
Condition
Takotsubo Cardiomyopathy
Condition
Beta-blockers
Condition
Echocardiography
Condition
Left Ventricular Function
Intervention (Drug)
Beta blocker
Lead sponsor
Spanish Society of Cardiology (class: other)
Collaborator
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa (class: other)

Record details

Record id
cardio:ct-nct06509074
Content hash
1b0a7bda24916f30679841ab1c30c501280aa1c796b4a192cae292884adc93a3